CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 123 enrolled
Drug / intervention
gas chromatography / tandem mass spectometryother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00975676
NCT00975676N/ACompleted
CompareCT.gov

A Substudy of the IBCSG 24-02/ SOFT Trial to Investigate Estrogen Suppression for Patients Participating in Arms B and C of the IBCSG 24-02/ SOFT Trial

ETOP IBCSG Partners Foundation·interventional·Posted Sep 11, 2009·Updated Oct 25, 2021

In Brief

A clinical study evaluating gas chromatography / tandem mass spectometry for Breast Cancer. Completed, enrolled 123 participants across 24 sites in 8 countries.

Detailed Summary

RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors learn how well triptorelin given together with tamoxifen citrate or exemestane works in lowering estrogen levels. PURPOSE: This clinical trial is studying estrogen levels in premenopausal women who have undergone surgery for breast cancer and are receiving triptorelin and tamoxifen citrate or exemestane on clinical trial IBCSG-2402.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesFrance, Hungary, Italy, Peru, Portugal, Spain, Sweden, Switzerland
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 11, 2009
Enrollment StartNov 25, 2008
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 16.8 years ago

Interventions

gas chromatography / tandem mass spectometryother

Determination of estrogen levels through gas chromatography.